Rhenman & Partners Asset Management AB Acquires 3,600 Shares of Thermo Fisher Scientific Inc. $TMO

Posted by Geri Gentry on Jun 13th, 2026

Rhenman & Partners Asset Management AB increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 12.0% during the fourth quarter, HoldingsChannel reports. The firm owned 33,640 shares of the medical research company’s stock after buying an additional 3,600 shares during the period. Thermo Fisher Scientific comprises 1.8% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 17th biggest holding. Rhenman & Partners Asset Management AB’s holdings in Thermo Fisher Scientific were worth $19,493,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Sumitomo Life Insurance Co. lifted its holdings in shares of Thermo Fisher Scientific by 5.3% during the fourth quarter. Sumitomo Life Insurance Co. now owns 28,470 shares of the medical research company’s stock valued at $16,497,000 after purchasing an additional 1,437 shares in the last quarter. Allianz SE lifted its holdings in shares of Thermo Fisher Scientific by 6.3% during the fourth quarter. Allianz SE now owns 16,528 shares of the medical research company’s stock valued at $9,577,000 after purchasing an additional 976 shares in the last quarter. SVRN Asset Management LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $304,000. Howland Capital Management LLC increased its position in Thermo Fisher Scientific by 0.6% during the fourth quarter. Howland Capital Management LLC now owns 76,207 shares of the medical research company’s stock valued at $44,191,000 after acquiring an additional 476 shares during the last quarter. Finally, Circle Wealth Management LLC increased its position in Thermo Fisher Scientific by 2.0% during the fourth quarter. Circle Wealth Management LLC now owns 4,623 shares of the medical research company’s stock valued at $2,679,000 after acquiring an additional 89 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on TMO shares. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Finally, Barclays reduced their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $608.95.

Check Out Our Latest Research Report on Thermo Fisher Scientific

Insider Buying and Selling

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $468.80 on Friday. The stock has a 50 day moving average of $479.14 and a 200 day moving average of $527.68. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The firm has a market cap of $174.22 billion, a PE ratio of 25.77, a PEG ratio of 2.11 and a beta of 0.88. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the prior year, the company earned $5.15 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.